EXACT SCIENCES CORP
EXASNasdaqHealthcare · Services-Medical Laboratories · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $3.25B | $2.76B | $2.50B | $2.08B | $1.77B | $1.49B |
| Operating income | −$206.3M | −$1.05B | −$215.0M | −$593.5M | −$855.7M | −$767.7M |
| Net income | −$207.9M | −$1.03B | −$204.1M | −$623.5M | −$595.6M | −$823.6M |
| Total assets | $5.86B | $5.93B | $6.47B | $6.23B | $6.68B | $4.93B |
| Total liabilities | $3.46B | $3.53B | $3.33B | $3.18B | $3.30B | $2.69B |
| Equity | $2.40B | $2.40B | $3.15B | $3.04B | $3.39B | $2.24B |
| EPS (diluted) | $-1.10 | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.45 |
| Shares out. | 185.8M | 181.5M | 178.2M | 174.1M | 169.1M | 148.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −6.4%
- Net margin
- −6.4%
- Return on equity
- −8.7%
- Return on assets
- −3.5%
- Return on capital (ROCE)
- −4.0%
- Liabilities / assets
- 59.0%
- Debt / equity
- 1.44×
- Book value / share
- $12.93
- Revenue growth (YoY)
- 17.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.10distress
- Accruals / assets
- −11.9%clean
- Beneish M-Score
- -2.86normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 26, 2026
- Capital World InvestorsPassive (13G)Feb 13, 2026
- Fmr LlcPassive (13G)Dec 5, 2025
- Wellington Management Group LlpPassive (13G)Nov 12, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Baranick BrianOfficer — EVP, GM, Precision Oncology | Mar 23, 2026 | Grant | 33,321 | $0.00 |
| Herriott JamesOfficer — SVP, General Counsel & Sec | Mar 23, 2026 | D | 68,195 | — |
| Bloomer AaronOfficer — EVP, Chief Financial Officer | Mar 23, 2026 | Grant | 89,911 | $0.00 |
| Condella SarahOfficer — EVP, Human Resources | Mar 23, 2026 | Grant | 60,389 | $0.00 |
| Conroy Kevin TOfficer — President and CEO | Mar 23, 2026 | Grant | 119,312 | $0.00 |
| Orville Jacob AOfficer — EVP, GM, Screening | Mar 23, 2026 | Grant | 53,323 | $0.00 |
| Coward D ScottDirector | Mar 23, 2026 | D | 52,164 | — |
| Petrovic ShaceyDirector | Mar 23, 2026 | D | 16,406 | — |
| Zanotti Katherine SDirector | Mar 23, 2026 | D | 55,361 | — |
| Popovits Kimberly JDirector | Mar 23, 2026 | D | 6,725 | — |
| Doyle James EdwardDirector | Mar 23, 2026 | D | 52,564 | — |
| Clancy Paul JDirector | Mar 23, 2026 | D | 20,640 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Mar 13, 2026 | 7.8M | 3.5 | +5.9% |
| Feb 27, 2026 | 7.4M | 3.9 | +3.9% |
| Feb 13, 2026 | 7.1M | 3.1 | +7.1% |
| Jan 30, 2026 | 6.6M | 2.7 | -11.9% |
| Jan 15, 2026 | 7.5M | 3.1 | -11.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMar 23, 2026
- Other material eventMar 20, 2026
- Shareholder voteFeb 20, 2026
- Results of operationsFeb 13, 2026
- Other material eventFeb 10, 2026
- Director / officer changeDec 29, 2025
- Entered a material agreement · Other material eventNov 20, 2025
- Results of operationsNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.